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Abstract
Background:  Fluorescence activated cell sorting (FACS) is a powerful technique for the qualitative and
quantitative detection of biomolecules used widely in both basic research and clinical diagnostic applications.
Beads displaying a specific antigen are used to bind antibodies which are then fluorescently labelled using
secondary antibodies. As the individual suspension bead passes through the sensing region of the FACS machine,
fluorescent signals are acquired and analysed. Currently, antigens are tediously purified and chemically cross-
linked to preformed beads. Purification and coupling of proteins often renders them inactive and they will not be
displayed in its native configuration. As an alternative, we genetically engineered Escherichia coli to produce
biopolyester (polyhdroxyalkanoate=PHA) granules displaying diagnostically relevant antigens in their native
conformation and suitable for FACS analysis.
Results: Hybrid genes were constructed, which encode either the mouse interleukin-2 (IL2) or the myelin
oligodendrocyte glycoprotein (MOG) fused via an enterokinase site providing linker region to the C terminus of
the PHA granule associated protein PhaP, respectively. The hybrid genes were expressed in PHA-accumulating
recombinant E. coli. MOG and IL2 fusion proteins were abundantly attached to PHA granules and were identified
by MALDI-TOF/MS analysis and N terminal sequencing. A more abundant second fusion protein of either MOG
or IL2 resulted from an additional N terminal fusion, which did surprisingly not interfere with attachment to PHA
granule. PHA granules displaying either IL2 or MOG were used for FACS using monoclonal anti-IL2 or anti-MOG
antibodies conjugated to a fluorescent dye. FACS analysis showed significant and specific binding of respective
antibodies. Enterokinase treatment of IL2 displaying PHA granules enabled removal of IL2 as monitored by FACS
analysis. Mice were immunized with either MOG or OVA (ovalbumin) and the respective sera were analysed using
MOG-displaying PHA granules and FACS analysis showing a specific and sensitive detection of antigen-specific
antibodies within a wide dynamic range.
Conclusion: E. coli can be genetically engineered to produce PHA granules displaying correctly folded eukaryotic
proteins and which can be applied as beads in FACS based diagnostics. Since PHA granule formation and protein
attachment occurs in one step already inside the bacterial cell, microbial production could be a cheap and efficient
alternative to commercial beads.
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Background
Polyhydroxyalkanoate (PHA) granules (biopolyester par-
ticles) are formed inside bacterial cells based on the activ-
ity and biochemical properties of the PHA synthases and
specific biosynthesis enzymes which are involved in PHA
precursor supply [1,2]. Biologically, PHA serves as a
reserve material. The PHA granule core is composed of
PHA and the surface of a phospholipid membrane with
embedded or attached proteins. Amphipathic phasin pro-
teins are one group of proteins specifically and hydropho-
bically interacting with the PHA core (for review see
[1,2]). The functional role of the phasins impacting on
PHA granule structure has been studied in detail [3-5].
Phasins and their fusion proteins have been increasingly
considered for protein production at the PHA granule sur-
face [2,6-8]. Recently, PHA synthase engineering enabled
production of the beta-galactosidase and GFP fusion pro-
teins, respectively, at the PHA granule surface [9,10]. The
GFP-PHA synthase fusion even enabled monitoring of in
vivo PHA granule formation indicating that PHA granule
formation starts at the cell poles. Only recently, PHA gran-
ules have been considered as spherical biopolyester parti-
cles which can be stably maintained outside the bacterial
cell exerting a size range from about 100 nm to several μm
[2,8].
Here we co-expressed the PHA biosynthesis operon from
Cupriavidus necator with a hybrid gene encoding a phasin
fusion protein in Escherichia coli in order to mediate the
formation of PHA granules efficiently displaying the
respective fusion partner. In this study, eukaryotic antigen
displaying PHA granules were designed and their applica-
tion performance with respect to diagnostic applications
using fluorescence activated cell sorting (FACS) was eval-
uated. The displayed myelin oligodendrocyte glycopro-
tein (MOG) was used as an example depicting diagnostic
analysis of the autoimmune disease multiple sclerosis
(MS). It was for the first time observed that surface-engi-
neered and antigen displaying PHA granules can be effi-
ciently used for FACS based diagnostics. Thus designed
PHA granules, which combine cheap one step production
with facilitated folding of proteins, might in future replace
commercial beads.
Results
Production of PhaP fused to IL2 or MOG at the PHA 
granule surface
The two immunologically and medically relevant proteins
MOG and IL2 derived from Mus musculus were each pro-
duced as PhaP fusion protein via construction of the
respective hybrid gene. The DNA sequences encoding
either MOG or IL2 were optimized with respect to the
codon usage of E. coli and purchased as synthetic DNA
fragment [see Additional file 1]. An enterokinase recogni-
tion site plus six histidine residues were inserted as linker
region between PhaP and IL2 or MOG in order to facilitate
independent folding of the fusion partner and to enable
specific removal of the antigen from the fusion partner.
Plasmids pBHR68-phaP-MOG and pBHR68-phaP-IL2,
which both comprise the entire PHB biosynthesis operon
in addition to the respective hybrid gene encoding the
PhaP fusion protein, were introduced into E. coli XL1 Blue
(Fig. 1, Table 1). The respective recombinant strains were
cultivated and PHA granules isolated. Proteins attached to
these granules were separated by SDS-PAGE and promi-
nent proteins were subjected to peptide fingerprinting
using MALDI-TOF/MS. Plasmid pBHR68-phaP-MOG
mediated the production of PHA granules showing four
prominent proteins with apparent molecular weights of
36 kDa, 39 kDa, 41 kDa and 43 kDa (Fig. 2). The 36 kDa
and the 39 kDa protein were strongly overproduced and
identified as PhaP-MOG fusion proteins using MALDI-
TOF/MS analysis (Fig. 2, Table 2). Both proteins were sub-
jected to N terminal amino acid sequencing and the 36
kDa PhaP-MOG fusion showed the expected N terminal
amino acid sequence MILTP, whereas the more abundant
39 kDa PhaP-MOG showed an N terminus of MTMITP.
The additional two more prominent proteins were sub-
jected to MALDI-TOF/MS analysis and identified the 43
kDa protein as EF-Tu (accession no. AP004451), but no
assignment of the 41 kDa could be obtained (data not
shown). Plasmid pBHR68-phaP-IL2 mediated the pro-
duction of PHA granules showing two prominent and
strongly overproduced proteins with apparent molecular
weights of 39 kDa and 42 kDa. Both proteins were identi-
fied as PhaP-IL2 fusion proteins using MALDI-TOF/MS
analysis (Table 2) and were subjected to N terminal
sequencing and the 39 kDa PhaP-MOG fusion showed the
expected N terminus of MILTP, whereas the more abun-
dant 42 kDa PhaP-MOG showed an N terminus of
MTMITP.
Batch cultivations led to the production of about 1 × 1011
PHA granules/L cultivation broth corresponding to about
3.0 g protein displayed at the PHA granules surface.
Native IL2 and MOG proteins were displayed on PHA 
granules
To test whether IL2 and MOG were expressed in native
form on the surface of the respective PHA granules, anti-
bodies that recognize correctly folded IL2 (PC61) or MOG
(8-18C5) and FACS technology were used [11,12]. The
size of PHA granules produced in E. coli has been reported
to be about 100–500 nm [1], and were detected in the for-
ward scatter (FSC) and 90° side scatter (SSC) detectors set
to list mode at a 256-channel resolution (data not
shown). PHA granules were incubated with unlabelled
mouse anti-MOG antibodies, followed by APC-labelled
anti-mouse IgG antibodies, or with PE-labelled anti-IL2BMC Biotechnology 2007, 7:3 http://www.biomedcentral.com/1472-6750/7/3
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Schematic view of plasmid constructs mediating production of antigen displaying PHA granules in E. coli Figure 1
Schematic view of plasmid constructs mediating production of antigen displaying PHA granules in E. coli. Trian-
gle represents the lac promoter. phaP, phasin gene; IL2, interleukin 2 gene; MOG, myelin oligodendrocyte glycoprotein encod-
ing gene; phaC, PHA synthase encoding gene; phaA, gene encoding β-kethothiolase; phaB, gene encoding acetoacetyl-CoA 
reductase.
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antibodies. The fluorescent intensity was then measured
using FACS technology. Results show that the mono-
clonal antibodies specifically recognized PHA granules
displaying the specific antigen, but not an un-related anti-
gen (Fig. 3). Both PC61 and 8-18C5 recognize only the
respective native protein indicating that correctly folded
IL-2 or MOG proteins were formed at the surface of the
respective PHA granules. These PHA granules showed
consistent performance in FACS analysis at least one year
when stored at 4°C.
PhaP-IL2 and PhaP-MOG fusion proteins containing the 
Asp-Asp-Asp-Asp-Lys recognition sequence are cleavable 
with enterokinase
To enable removal and/or purification of recombinant
eukaryotic proteins, which form inactive inclusion bodies
in E. coli, an enterokinase recognition sequence encoding
for the Asp-Asp-Asp-Asp-Lys peptide was incorporated
immediately downstream of PhaP. To determine if the
recognition sequence was readily accessible, PhaP-IL2 and
PhaP-MOG containing PHA granules were incubated for
16 h with enterokinase. Samples of PhaP-IL2 and PhaP-
MOG granules were removed before, after 1 h and after 16
h of incubation with enterokinase to determine the level
of native protein remaining at the surface of the respective
PHA granule. PhaP-IL2 and PhaP-MOG granules were
incubated with PE-conjugated anti-IL2 and samples ana-
lysed by FACS (Fig. 4A). A similar pattern of decreased
protein levels after incubation with enterokinase was
found with PhaP-MOG granules incubated with anti-
MOG monoclonal antibodies (data not shown). The level
of IL2 was reduced by ~80% after 1 h incubation and after
16 h incubation no significant levels of IL2 protein were
detectable at the surface of the granules (Figure 4B). Over-
all, results shown in Figures 3 and 4 demonstrate that cor-
rectly folded recombinant proteins can be expressed as a
fusion protein together with PhaP and that the fusion
partner can be completely removed by enterokinase treat-
ment.
PHA granules displaying PhaP-MOG fusion proteins were 
used in FACS-based assays to detect antigen-specific serum 
antibodies
Since PHA granules can be detected using FACS technol-
ogy, we tested whether PhaP-MOG granules could be used
to detect and quantify the level of antigen-specific anti-
bodies from immunized animals. For this purpose, mice
were immunized with recombinant MOG or OVA protein
in CFA to induce an antibody response to MOG and OVA,
respectively. Twenty-eight days post immunization, mice
were tail-bled and immune sera collected. Sera from five
different mice were pooled and tested for binding to
PhaP-MOG granules. Results in Figure 5A showed that
MOG-immunized, but not OVA-immunized, anti-sera
contained antigen-specific IgG antibodies that recognized
the PhaP-MOG fusion protein. The sera could be diluted
>1:105 fold and still showed a significant binding of IgG
to the PhaP-MOG granules (Figure 5B). Sera from OVA-
immunized mice did not bind significantly to PhaP-MOG
granules. However, OVA immunized mice produced
OVA-specific IgG, as micro-titre wells coated with OVA,
but not with MOG, showed bound IgG which was easily
detectable using ELISA (Figure 5C). These results illustrate
that recombinant eukaryotic proteins displayed with
Table 1: Bacterial strains, plasmids and oligonucleotides used in this study
Strains Genotype Source or reference
Escherichia coli recA1, endA1, gyrA96, thi-1, hsdR17 (rk
-, mk
+), [16]
XL1-Blue supE44, relA1, -, lac [F', proAB, lacIq, lacZΔM15, Tn10(Tcr)]
Cupriavidus necator H16 Wildtype (PHA+) DSMZ 428
Plasmids
pCRII Amp, ColE1 origin Initrogen
pBHR68 PHB biosynthesis operon from C. necator in pBluescriptSK- [17]
pHAS pET-14b containing NdeI/BamHI inserted phaC gene from C. necator [18]
pUC57-MOG DNA fragment encoding N terminal 1–173 amino acids of MOG from mouse inserted in SmaI site of pUC57 This study
pUC57-IL2 DNA fragment encoding N terminal 60–169 amino acids of IL2 from mouse inserted in SmaI site of pUC57 This study
pCR-phaP pCRII containing phaP gene from C. necator This study
pHAS-phaP pHAS containing the phaP gene inserted into XbaI/NdeI sites This study
pHAS-phaP-MOG pHAS-phaP containing the MOG encoding DNA fragment inserted into NdeI/BamHI sites This study
pHAS-phaP-MOG pHAS-phaP containing the IL2 encoding DNA fragment inserted into NdeI/BamHI sites This study
pUC57-phaP-MOG DNA fragment encoding PhaP inserted into XbaI and NdeI site of plasmid pUC57-MOG This study
pUC57-phaP-IL2 DNA fragment encoding PhaP inserted into XbaI and NdeI site of plasmid pUC57-IL2 This study
pBHR68-phaP-MOG DNA fragment encoding PhaP-MOG fusion protein subcloned from pUC57-phaP-MOG via XbaI and BamHI into pBHR68 This study
pBHR68-phaP-IL2 DNA fragment encoding PhaP-IL2 fusion protein subcloned from pUC57-phaP-IL2 via XbaI and BamHI into pBHR68 This study
Oligonucleotides
phaP-XbaI-NdeI 5'-aaaaatctagaaaaaggagatatacatatgatcctc-accccggaacaag-3' This study
phaP-XbaI 5'-aaaaatctagaaaaaggagatatacgtatgatcctc-accccggaacaag-3' This study
phaP-NdeI 5'-aaaaacatatggtggtgatggtgatgcgagccgcgt-ttatcatcatcatcggcagccgtcgtcttc-3' This studyBMC Biotechnology 2007, 7:3 http://www.biomedcentral.com/1472-6750/7/3
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SDS-PAGE analysis of PHA granule attached proteins Figure 2
SDS-PAGE analysis of PHA granule attached proteins. Proteins were identified by peptide fingerprinting using MALDI-
TOF/MS and N terminal amino acid sequencing. LacZ' represents the N terminal 33 amino acid residues of LacZ. M, molecular 
weight standard; 1, PHA granules isolated from E. coli harbouring plasmid pBHR68-phaP-MOG; 2, PHA granules isolated from 
E. coli harbouring plasmid pBHR68-phaP-IL2.
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PhaP as a fusion protein can be applied using FACS tech-
nology to detect and quantify the level of antigen-specific
antibodies from vaccinated animals.
Discussion
In this study, the surface of PHA granules produced by
recombinant E. coli was subjected to protein engineering
to display natively folded eukaryotic proteins, which serve
as antigens in diagnostics (Fig. 6). Both chosen eukaryotic
proteins MOG and the cytokine IL-2 form inclusion bod-
ies upon production in E. coli [13,14]. A microbial protein
production system avoiding the formation of inclusion
bodies would have a huge advantage by circumventing
the tedious process of solubilization and refolding. The
PHA granule attached structural protein PhaP was N ter-
minally fused to either MOG or IL2 (Fig. 1). A strong over-
production under lac promoter control of the respective
fusion proteins could be observed (Fig. 2). The fusion pro-
teins could be identified by peptide fingerprinting using
MALDI-TOF/MS analysis and by N terminal amino acid
sequencing. Interestingly, the fusion proteins appeared in
two versions with different apparent molecular weight.
The smaller molecular weight version of the fusion pro-
tein showed the theoretical molecular weight of the
respective fusion protein. The N terminal sequence
(MTMITP) of the larger molecular weight version sug-
gested that the N terminal 33 amino acid residues (theo-
retical molecular weight of 3.4 kDa) of LacZ were fused to
the N terminus of PhaP fusion protein based on start
codon upstream of the start codon of the hybrid gene
encoding the PhaP-MOG or PhaP-IL2. This was also in
accordance with the apparent molecular weight difference
of 3.5 kDa between the two versions. Interestingly, the
LacZ'-PhaP-MOG/IL2 fusion proteins were more abun-
dant than the respective single fusions (Fig. 2). These data
suggest that N terminal fusions to PhaP do not interfere
with the binding to the PHA core of PHA granules and
that the copy numbers can be even enhanced. This is
unexpected considering the current phasin protein model
[5]. The presence of the two E. coli proteins 41 kDa and
EF-Tu at the MOG displaying PHA granule surface might
be due to an unspecific interaction with PHA granule sur-
face, which has been already observed elsewhere [10]. In
contrast to a previous study, where multiple copies of
PhaP were required for binding of prokaryotic protein
fusions, a single copy was sufficient using an enterokinase
site linker and eukaryotic proteins [6].
Engineered PHA granules were subjected to FACS analysis
using antibodies specifically recognizing the respective
native protein folds, which showed the display of the
natively folded eukaryotic proteins MOG and IL2 at the
PHA granule surface as well as the applicability of
designed PHA granules for FACS-based diagnostics (Fig.
3). Although MOG and IL2 are secreted proteins, the
derived protein domains were properly folded attached to
the PHA granule in the reducing cytosol of E. coli while
avoiding the formation of protein inclusion bodies.
Although E. coli strains (e.g. Origami) are available, which
provide an oxidative cytosol, protein overproduction
often leads to inclusion body formation. Enterokinase
treatment of MOG or IL2 displaying PHA granules and the
complete release of the antigen suggested that the respec-
tive antigen was exposed at the PHA granule surface (Fig.
4). This surface exposure enables efficient antigen specific
antibody binding. To evaluate the suitability of MOG or
IL2 displaying PHA granules for qualitative and quantita-
tive FACS-based antibody detection, mice were immu-
nized with MOG or OVA (control) and induction of
specific antibody production was assessed and confirmed
by ELISA (Fig. 5). These MOG or OVA antisera were ana-
lysed using the MOG displaying PHA granules and FACS
technology, which clearly indicated that anti-MOG anti-
bodies can be specifically detected at least up to an antis-
era dilution of 1:100,000 (Fig. 5). In this study, it was
demonstrated that eukaryotic proteins can be functionally
displayed at the PHA granule surface using protein engi-
neering of PhaP. Evidence was provided that the fusion
proteins (antigens) were exposed at the PHA granule and
thus PHA granules could be used to capture antibodies.
This feature in combination with the particle properties of
the PHA granules led to an outstanding performance in
FACS based diagnostics, particularly considering the sig-
nal to noise ratio and dynamic range of antibody detec-
Table 2: Identified peptide fragments of proteins analyzed by MALDI-TOF/MS
protein peptide fragments
LacZ'-PhaP-IL2 A91-Y120, E96-A114, E121-E135, E190-T218,
PhaP-IL2 A57-Y86, E62-A80, E87-E101, E156-T184, L300-G320
LacZ'-PhaP-MOG N15-M34, W18-M34, L89-H118, A94-H118, L119-N155, L113-V133, A156-S169, T185-T216, A188-T216, T222-G232, 
G247-L255, T273-P283, V289-R308
PhaP-MOG L55-H84, A60-H84, L85-N121, L79-V99, A122-S135, A154-T182, A173-T188, G247-L255, T273-P283, T275-V288, V289-
R308.BMC Biotechnology 2007, 7:3 http://www.biomedcentral.com/1472-6750/7/3
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tion. It was recently shown that ZZ domain displaying
PHA granules, which were produced via protein engineer-
ing of the PHA synthase, were suitable for IgG purification
[15]. When compared to commercial beads, engineered
PHA granules showed increased sensitivity with similar
distribution of signal intensities in FACS. Overall, protein
engineering of PHA granule surface proteins provides a
novel molecular tool for the display of antigens for FACS-
based diagnostics.
Conclusion
In this study, it was demonstrated that correctly folded
eukaryotic proteins can be abundantly produced at the
PHA granule surface as phasin fusion proteins. Isolated
PHA granules displaying the respective eukaryotic pro-
teins could be used as beads for specific and sensitive anti-
body detection using FACS technology. These native
antigen displaying PHA granules were manufactured by
recombinant E. coli without the need of antigen purifica-
tion and chemical cross-linking to independently pro-
duced beads. Often purification of these proteins requires
tedious refolding at low efficiency. The production of
functional eukaryotic proteins at the PHA granule surface
represents a novel in vivo matrix-assisted protein folding
system avoiding aggregation of protein folding intermedi-
ates. Moreover, PHA granules could be stored for at least
one year at 4°C without loss of performance in FACS sup-
porting their potential use in diagnostic applications.
This work opens up an alternative route for the produc-
tion of protein displaying beads harnessing nature's
capacity to produce spherical polymer beads which sur-
face can be functionalized by engineering of specifically
bead associating proteins (Fig. 6). Multiple functionality
might be easy achievable by co-expression of various
hybrid genes suggesting that this biotechnological bead
production strategy might represent a versatile platform
technology.
Methods
Bacterial strains and growth conditions
Bacterial strains, plasmids and oligonucleotides used in
this study are listed in Table 1. Cupriavidus necator and E.
coli XL1 Blue were grown at 37°C. When required, ampi-
PHA granules display the native eukaryotic proteins Figure 3
PHA granules display the native eukaryotic proteins. PhaP-IL2 and PhaP-MOG granules were produced as described in 
Materials and Methods. Approximately 5 × 108 PhaP-IL2 or PhaP-MOG granules were incubated with PC61 (anti-IL2) or 8-
18C5 (anti-MOG) antibodies. Samples were collected using a FACsCalibur and then analyzed on FlowJo software. The data 
were depicted in a "normalized" fashion (% of Maximum). The % of Max is the number of cells in each bin divided by the 
number of cells in the bin that contains the largest number of cells. One representative experiment of at least three independ-
ent experiments, which showed no significant differences, is shown.
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cillin 75 μg/ml was added. All chemicals were purchased
from Sigma-Aldrich (St. Louis, Mo., USA).
Isolation, analysis and manipulation of DNA
General cloning procedures and isolation of genomic
DNA were performed as described elsewhere [19]. DNA
primers, deoxynucleoside triphosphate, Taq and Platinum
Pfx polymerases were purchased from Invitrogen™ (CA,
USA). DNA sequences of new plasmid constructs were
confirmed by DNA sequencing according to the chain ter-
mination method using the model ABI310 automatic
sequencer. Plasmids used in this study are listed in Table
1.
Construction of plasmids mediating production of either 
IL2 or MOG displaying PHA granules
The DNA fragments encoding either the full length
mature IL2 protein (amino acids 60–169, accession no.
AAN38301) or the extracellular part of the MOG protein
(amino acids 1–117, accession no. Q61885) from mouse
were synthesized by GenScript Corp. (USA). The codon
usage was optimized for expression in E. coli [see Addi-
tional file 1]. Each DNA fragment contained an NdeI site
at the 5' end and a BamHI site at the 3' end. These DNA
fragment were inserted into the SmaI site of pUC57
directly after synthesis by GenScript Corp. (USA) resulting
in plasmids pUC57-MOG or pUC57-IL2, respectively. The
Enterokinase treatment of antigen displaying PHA granules and FACS analysis Figure 4
Enterokinase treatment of antigen displaying PHA granules and FACS analysis. PhaP-IL2 and PhaP-MOG granules 
were incubated with enterokinase for the indicated period of time, washed and then tested for the amount of native proteins 
remaining at the surface of the granules. In (A), the anti-IL2 PC61 and anti-MOG 8-18C5 monoclonal antibodies were used for 
this purpose as described for Figure 1. In (B), the percentage of IL2 protein detected after 1 and 16 hours incubation with 
enterokinase is shown. The data was depicted in a "normalized" fashion (% of Max). One representative experiment of at least 
three performed experiments, which showed no significant differences, is depicted. After overnight incubation no detectable 
staining using fluorescent anti-IL2 antibodies could be observed.
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coding region of phaP1 gene was amplified by PCR from
chromosomal DNA of C. necator using oligonucleotides
phaP-XbaI-NdeI and phaP-NdeI listed in Table 1 and
introducing an XbaI site at the 5' end and an NdeI site
including an enterokinase site at the 3' end. The PCR
product was subcloned into TA cloning plasmid pCRII.
The phaP coding region was again amplified from plasmid
pCR-phaP using oligonucleotides phaP-XbaI including an
E. coli ribosomal binding site and phaP-NdeI. The result-
ing PCR product was subcloned into the XbaI and NdeI
sites of pHAS.
Either pUC57-MOG or pUC57-IL2 was hydrolyzed with
NdeI and BamHI and the corresponding DNA fragments
were subcloned into pHAS-phaP resulting in plasmids
pHAS-phaP-MOG and pHAS-phaP-IL2, respectively. The
respective fusion protein encoding region was then sub-
cloned into pBHR68 using XbaI and BamHI sites down-
FACS-based detection of antigen-specific antibodies using antigen displaying PHA granules Figure 5
FACS-based detection of antigen-specific antibodies using antigen displaying PHA granules. In (A), MOG-phaP 
granules were incubated with serial dilutions of pooled antisera from five MOG or OVA immunized mice. Granules were 
extensively washed and then incubated with biotinylated anti-mouse IgG, followed by PE-conjugated streptavidin. The data was 
depicted in a "normalized" fashion (% of Max). One representative experiment, of at least two experiments performed, is 
depicted. In (B), the mean channel fluorescent for each dilution of antisera from MOG or OVA immunized mice binding to 
MOG-phaP was measured and depicted. In (C), ELISA was performed on anti-sera from MOG- and OVA-immunized mice. 
Serial dilutions of the anti-sera were added to MOG- or OVA-coated wells and incubated for 30 minutes. Biotinylated anti-
mouse IgG was then added to the washed wells, followed by HRP-conjugated streptavidin and TMB substrate. The optical den-
sity was read at 450 nm and the results from one representative experiment, of at least two experiments performed, are 
shown. In (C), data are displayed as mean ± SEM from triplicate samples.
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Schematic view of the microbial production of antigen displaying PHA granules and their use in FACS analysis Figure 6
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stream of the lac  promoter and upstream of the PHB
biosynthesis operon (Fig. 1).
Production of phasin fusion proteins at the PHA granule 
surface
Cells of E. coli XL1 Blue were transformed with plasmids
pBHR68-PhaP-IL2 and pBHR68-PhaP-MOG, respectively.
Transformants were grown at 37°C and induced by add-
ing isopropyl-β-D-thiogalactopyranoside (IPTG) to a final
concentration of 1 mM. After growth for 48 h, cells were
harvested by centrifugation and subjected to PHA granule
isolation.
Isolation of PHA granules
Cells were harvested by centrifugation for 15 min at 5,000
× g and 4°C. The sediment was washed and suspended in
3 volumes of 50 mM phosphate buffer (pH7.5). Cells
were passed through French Press four times at 8000 psi.
The cell lysate (0.75 ml) was loaded onto a glycerol gradi-
ent (88 % and 44 % (v/v) glycerol in phosphate buffer).
After ultracentrifugation for 2.5 h at 100,000 × g and
10°C, granules could be isolated from a white layer above
the 88 % glycerol layer. The PHA granules were washed
with 10 volumes phosphate buffer (50 mM, pH7.5) and
centrifuged at 100,000 × g for 30 min at 4°C. The sedi-
ment containing the PHA granules was suspended in
phosphate buffer and stored at 4°C.
Sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE)
Protein samples were routinely analyzed by SDS-PAGE as
described elsewhere [20]. The gels were stained with
Coomassie brilliant blue G250. Protein bands of interest
were cut off the gel and analyzed by matrix assisted laser
desorption/ionization time-of flight mass spectrometry
(MALDI TOF-MS).
MALDI-TOF mass spectrometry
Mass spectrometric analyses of tryptic peptides were car-
ried out on a MALDI VOYAGER DE-PRO time of flight
mass spectrometer from PerSeptive BioSystems (Framing-
ham, MA) utilizing a nitrogen laser, emitting at 337 nm,
and an accelerating voltage of 25 kV. Measurements were
performed in the delayed extraction mode using a low
mass gate of 2000. The mass spectrometer was used in the
positive ion detection and linear mode. Samples of the
digestion mixture were placed directly on a 100-position
sample plate, and allowed to air-dry after the addition of
an equal volume of saturated solution of 3,5-dimethoxy-
4-hydroxycinnaminic acid (sinapinic acid) in 50% ace-
tonitrile and 0.3% TFA.
Mice
C57BL/6 mice were originally purchased from the Jackson
Laboratory (Bar Harbor, ME). All mice were maintained
by the Biomedical Research Unit, Malaghan Institute of
Medical Research, Wellington, New Zealand. Experimen-
tal protocols were approved by the Victoria University of
Wellington Animal Ethics Committees and performed
according to the guidelines of their guidelines. In all
experiments, sex and age matched mice were used
between 8–12 weeks of age.
Mouse serum IgG responses
C57BL/6 mice were immunized with 150 μg recombinant
mouse MOG protein consisting of amino acid 1–117
(MOG1–117) of the matured protein [21] or 150 μg oval-
bumin protein (OVA, Sigma-Aldrich) emulsified in Com-
plete Freund's adjuvant (CFA), containing 500 μg
Mycobacterium tuberculosis (both DIFCO Laboratories).
The emulsion (100 μl) was injected subcutaneously over
the flanks. Blood was collected from tail bleeds 28 days
post-immunization, centrifuged at 13,000 g for 1 min,
and then the top layer of serum was removed and stored
at -20°C. Serum was tested for antigen-specific total IgG,
using the PhaP-MOG granules and flow cytometry or
ELISA (see below).
Cleavage of IL2 from IL2 displaying PHA granules
The enterokinase recognition sequence Asp-Asp-Asp-Asp-
Lys was introduced between PhaP and IL-2 to enable
cleavage of the IL-2 protein from the granules. Twenty-five
μg of bovine enterokinase (Sigma-Aldrich, E-5144) in 10
mM Tris/HCl, 10 mM CaCl2 (pH8) were incubated with 2
× 1010 PhaP-IL2 or PhaP-MOG granules at 37°C, and at
indicated time points samples were removed, washed
with PBS, and stored at 4°C until use. The relative amount
of native IL2 and MOG at the surface of the granules was
determined using flow cytometry.
Flow cytometry
PhaP-MOG or PhaP-IL2 granules (~5 × 108/well) were
added to 96-well round-bottom plates (Becton, Dickin-
son and Company) and washed twice with FACS-buffer
(PBS, 1% Foetal calf serum, 0.1% sodium azide, 5 mM
EDTA, pH8). IL2-phaP or MOG-phaP granules were then
incubated with phycoerythrin conjugated anti-IL2 mono-
clonal antibody (clone PC61, PharMingen) or a mouse
anti-MOG monoclonal antibody (clone 8.18-C5, kindly
provided by C. Bernard). Following 15 minutes incuba-
tion at ambient temperature, granules were washed twice
in fluorescence activated cell sorting (FACS) buffer. Allo-
phycocyanin-conjugated anti-mouse IgG (Jackson Immu-
noResearch Laboratories Inc.) polyclonal antibodies were
added to the MOG displaying PHA granules and incu-
bated for 15 minutes, and then washed twice. At least
10,000 events for each sample were collected and ana-
lysed, using a BD FACsCAlibur and FlowJo analysis soft-
ware (Tree Star, San Carlos, CA, USA). For detection of
MOG-specific antibody responses, sera from MOG orBMC Biotechnology 2007, 7:3 http://www.biomedcentral.com/1472-6750/7/3
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OVA immunized mice were diluted in FACS-buffer and
then incubated for 30 minutes at ambient temperature
with MOG-phaP granules. The granules were then washed
and incubated with biotinylated anti-mouse total IgG, fol-
lowed by PE-conjugated streptavidin. At least 10,000
events for each sample were collected and analysed on a
BD FACsCAlibur and FlowJo software (Tree Star).
ELISA
Round-bottom 96-well plates (Becton, Dickinson and
Company) were coated overnight at 4°C (50 μl/well) with
3 μg/ml of recombinant mouse MOG1–117or OVA protein
(Sigma-Aldrich) in PBS. Supernatant was discarded and
wells blocked by adding 1% BSA in PBS (100 μl/well) for
1 h at ambient temperature. Plates were then wash 3 times
with 10 mM Tris/HCl, pH 7.5, 0.05% Tween 20 (ELISA
buffer). Diluted sera (50 μl/well) in 0.1% BSA/PBS from
MOG1–117 or OVA immunized mice were added and after
2 h, plates were washed 3 times with ELISA buffer. Biotin-
conjugated anti-mouse IgG antibodies (Southern Biotech-
nology, Ltd) diluted 1:4,000 in 0.1% BSA/PBS were added
for 1 h, and wells then wash 3 times with ELISA buffer.
Amdex Streptavidin-HRP (Amersham Biosciences)
diluted 1:3,000 in 0.1% BSA/PBS, was added to each well
(50 μl/well) and incubated for 30 minutes. Plates were
then wash 3 times and 3,3',5,5'-tetramethylbenzidine
(TMB) added for 5–30 minutes. Colour development was
stopped using 2 M H2SO4 and the ELISA plates were then
read at 450 nm on a Benchmark microplate reader (Bio-
Rad Laboratories Inc. Hercules, CA, USA).
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